BCL2L1 and neoplasm: In non‐small cell lung cancer, the dual application of ABT‐263, which also inhibits Bcl‐2, Bcl‐xl, and Bcl‐w, with gemcitabine has shown improved therapeutic outcomes by effectively reducing tumor growth and increasing survival rates in preclinical models.34